Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)
Stopped early · Phase 2
Conditions studied: Metastatic Colorectal Cancer
In brief
The goals of this clinical study are to learn more about the safety, tolerability and effectiveness of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC). The primary objectives of this study are: (safety run-in cohort) to evaluate safety and tolerability, and the recommended Phase 2 dose (RP2D) and (randomized cohort) to evaluate the efficacy of magrolimab in combination with bevacizumab and 5-fluorouracil, irinotecan, and leucovorin (FOLFIRI) in previously treated participants with advanced inoperable metastatic colorectal cancer (mCRC).
Key facts
- Study ID
- NCT05330429
- Run by
- Gilead Sciences
- People needed
- 77
- Starts
- 2022-07-08
- Expected to finish
- 2024-06-26
- Last updated by the study team
- 2025-07-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- City of Hope ( City of Hope National Medical Center, City of Hope Medical Center ) — Duarte, California, United States
- USC Norris Comprehensive Cancer Center — Los Angeles, California, United States
- Stanford Cancer Center — Palo Alto, California, United States
- Torrance Memorial Physician Network — Redondo Beach, California, United States
- University of California Los Angeles (UCLA) — Santa Monica, California, United States
- Orlando Health Cancer Institute — Orlando, Florida, United States
- Fort Wayne Medical Oncology and Hematology, Inc. — Fort Wayne, Indiana, United States
- University of Kansas — Westwood, Kansas, United States
- University of Michigan — Ann Arbor, Michigan, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
- Hematology Oncology Associates of Central New York, PC — East Syracuse, New York, United States
- AdventHealth — Rochester, New York, United States
- Pennsylvania Hospital — Philadelphia, Pennsylvania, United States
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States
- Avera Cancer Institute — Sioux Falls, South Dakota, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Texas Oncology — Dallas, Texas, United States
- Baylor College of Medicine Medical Center — Houston, Texas, United States
- Virginia Cancer Specialists, PC — Arlington, Virginia, United States
- Seattle Cancer Care Alliance (SCCA) — Seattle, Washington, United States
- Westmead Hospital — Blacktown, New South Wales, Australia
- Kinghorn Cancer Centre — Darlinghurst, New South Wales, Australia
- Southside Cancer Care Centre — Miranda, New South Wales, Australia
- Genesis Care North Shore — St Leonards, New South Wales, Australia
- Austin Health — Heidelberg, Victoria, Australia
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.